Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acyline + testosterone undecanoate
- Development stage
- Unknown
- Lead developer
- University of Washington
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Acyline + testosterone undecanoate is a combination hormonal regimen developed by the University of Washington for use as a male contraceptive. The regimen utilizes acyline, a potent gonadotropin-releasing hormone (GnRH) receptor antagonist, to suppress the hypothalamic-pituitary-gonadal axis. This suppression inhibits the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), effectively halting endogenous testosterone production and spermatogenesis. To compensate for the loss of endogenous testosterone and prevent symptoms of hypogonadism, a novel oral formulation of testosterone undecanoate (TU) is co-administered as androgen replacement therapy. This specific combination was evaluated in Phase 2 clinical trials to determine the pharmacokinetics and efficacy of oral TU in maintaining serum testosterone levels within the physiological range while sperm production is suppressed.
- Other names
- Acyline + TUAcyline + Testosterone undecanoate
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on acyline + testosterone undecanoate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acyline + testosterone undecanoate.